Negotiable: SRG: Clinical Recruitment ConsultantSalary: Negotiable. dependant on experience + Bonus + BenefitsLocation: Hybrid, UKSRG is the UK's number one speciali Homeworking

Funding Opportunity RFA-DA-24-039 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the development of innovative tools and/or technologies to monitor or manipulate biomolecular condensates (BMCs) in vivo and enable investigators to adopt these tools to answer outstanding questions in basic neuroscience. This research will transform our understanding of the mechanistic role of BMCs in human nervous system health and disease and may serve as the foundation for the development of novel BMC-based therapeutics.

Funding Opportunity PAR-23-145 from the NIH Guide for Grants and Contracts. The Maximizing Investigators' Research Award (MIRA) under this Notice of Funding Opportunity (NOFO) provides support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this NOFO, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding.

Notice NOT-OD-23-110 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-179 from the NIH Guide for Grants and Contracts. This Small Research Grant (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

Notice NOT-HG-23-036 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-035 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This FOA seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.

Funding Opportunity RFA-CA-23-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (NOFO) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Notice NOT-CA-23-061 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-008 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-118 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-059 from the NIH Guide for Grants and Contracts

Negotiable: AstraZeneca : Senior Scientist, Image Analysis to work within our Computational Pathology, Oncology team. Munich, Germany

Notice NOT-RM-23-012 from the NIH Guide for Grants and Contracts

Notice NOT-RM-23-011 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-109 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-111 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-115 from the NIH Guide for Grants and Contracts

Conduct metagenomic analysis and sequencing analysis. Experience in microbial ecology, molecular methods and/or bioinformatics to characterized mixed microbial…
From Marquette University - Thu, 20 Apr 2023 22:22:36 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-CA-24-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria.This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.